UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology

The lancet oncology, 2018-06, Vol.19 (6), p.e317-e326

2018

Volltextzugriff (PDF)

Assessing capacity to consent for research in cognitively impaired older patients

Clinical interventions in aging, 2017-01, Vol.12, p.1553-1563

2017

Volltextzugriff (PDF)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?

EBioMedicine, 2020-11, Vol.61, p.103046-103046, Article 103046

2020

Volltextzugriff (PDF)

Toxicity of Cancer Therapies in Older Patients

Current oncology reports, 2018-08, Vol.20 (8), p.64-11, Article 64

2018

Volltextzugriff (PDF)

The genomic trajectory of ovarian high‐grade serous carcinoma can be observed in STIC lesions

The Journal of pathology, 2024-09, Vol.264 (1), p.42-54

2024

Volltextzugriff (PDF)

Cross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in France

Clinical epidemiology, 2015-01, Vol.7 (default), p.431-440

2015

Volltextzugriff (PDF)

Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy

Current oncology reports, 2021-12, Vol.23 (12), p.148-148, Article 148

2021

Volltextzugriff (PDF)

Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial

Nature communications, 2024-07, Vol.15 (1), p.5931-11, Article 5931

2024

Volltextzugriff (PDF)

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges

Frontiers in oncology, 2024-03, Vol.14, p.1354427-1354427

2024

Volltextzugriff (PDF)

Is There an Age Threshold for Holding Off on Testing Novel Therapies?

Current oncology reports, 2018-01, Vol.20 (1), p.6-7, Article 6

2018

Volltextzugriff (PDF)

600 Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacy

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A190-A191

2024

Volltextzugriff (PDF)

856 Routine baseline blood tests predicting pembrolizumab sensitivity in advanced high-grade serous ovarian cancer (AHGSOC) 1st line therapy: substudy from the NEOPEMBROV/GINECO (NCT03275506) randomized trial

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A372-A373

2024

Volltextzugriff (PDF)

Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer

Future oncology (London, England), 2021-06, Vol.17 (18), p.2291-2304

2021

Volltextzugriff (PDF)

Heterogeneity and Functions of Tumor-Infiltrating Antibody Secreting Cells: Lessons from Breast, Ovarian, and Other Solid Cancers

Cancers, 2022-09, Vol.14 (19), p.4800

2022

Volltextzugriff (PDF)

Cancers de l’ovaire. Des nouvelles molécules pour chaque type histologique ou moléculaire, une avancée vers plus de guérison ?

Bulletin de l'Académie nationale de médecine, 2024-10, Vol.208 (8), p.1101-1106

2024

Volltextzugriff (PDF)

Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients

Cancer chemotherapy and pharmacology, 2018-08, Vol.82 (2), p.319-327

2018

Volltextzugriff (PDF)

Actualités autour des inhibiteurs de checkpoints immunitaires : enseignements issus du congrès ASCO 2017 et perspectives

Bulletin du cancer, 2018-07, Vol.105 (7-8), p.686-695

2018

Volltextzugriff (PDF)

Optimal management of breast cancer in the elderly patient: current perspectives

Clinical interventions in aging, 2015-01, Vol.10, p.157-174

2015

Volltextzugriff (PDF)

Les avancées actuelles de l’immunothérapie dans le cancer de l’ovaire

Bulletin du cancer, 2020-04, Vol.107 (4), p.465-473

2020

Volltextzugriff (PDF)

Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer

OncoTargets and therapy, 2013-01, Vol.6 (default), p.89-94

2013

Volltextzugriff (PDF)

Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer

Seminars in cancer biology, 2021-12, Vol.77, p.127-143

2021

Volltextzugriff (PDF)

Inclusion of elderly patients in oncology clinical trials

Annals of oncology, 2016-09, Vol.27 (9), p.1799-1804

2016

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(49)
Buchkapitel
(2)

Sprache

Englisch
(48)
Französisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology

Assessing capacity to consent for research in cognitively impaired older patients

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?

Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network

Toxicity of Cancer Therapies in Older Patients

The genomic trajectory of ovarian high‐grade serous carcinoma can be observed in STIC lesions

Cross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in France

Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy

Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges

Is There an Age Threshold for Holding Off on Testing Novel Therapies?

Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma

600 Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacy

856 Routine baseline blood tests predicting pembrolizumab sensitivity in advanced high-grade serous ovarian cancer (AHGSOC) 1st line therapy: substudy from the NEOPEMBROV/GINECO (NCT03275506) randomized trial

Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer

Heterogeneity and Functions of Tumor-Infiltrating Antibody Secreting Cells: Lessons from Breast, Ovarian, and Other Solid Cancers

Cancers de l’ovaire. Des nouvelles molécules pour chaque type histologique ou moléculaire, une avancée vers plus de guérison ?

Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients

Actualités autour des inhibiteurs de checkpoints immunitaires : enseignements issus du congrès ASCO 2017 et perspectives

Optimal management of breast cancer in the elderly patient: current perspectives

Les avancées actuelles de l’immunothérapie dans le cancer de l’ovaire

Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial

Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer

Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer

Inclusion of elderly patients in oncology clinical trials

Suchergebnisse filtern